For prediction of IDH mutation status (Table 1), the image fusion model incorporating radiomic signatures based on contrast-enhanced T1-weighted imaging (cT1WI) and apparent diffusion coefficient (ADC) achieved the highest value, which was significantly superior to a clinical model based on age and tumor location (P < 0.001 in the training and P = 0.002 in the validation cohort). This evidence concerns the gene IDH2 and neoplasm.